Navigation Links
PharmaSURVEYOR's Advanced Drug Safety Service Connects to Microsoft HealthVault
Date:6/11/2009

Personalized drug assessment tool allows members to identify, diagnose and resolve drug side effects and interactions

SEATTLE, June 11 /PRNewswire/ -- PharmaSURVEYOR (http://www.pharmasurveyor.com) announced the integration of their Advanced Drug Safety service with Microsoft HealthVault at the Microsoft Connected Health Conference. PharmaSURVEYOR offers a personalized drug assessment tool designed to show users not only drug-drug interactions but the much more common and often dangerous adverse drug side effects. HealthVault users will be able to run a survey of medications stored in their HealthVault account and PharmaSURVEYOR users will be able to easily create a HealthVault account to store their medications.

"PharmaSURVEYOR is proud to join the growing ecosystem of services connected by HealthVault," said Erick Von Schweber, Executive Co-Chair of PharmaSURVEYOR. "For example, a consumer can download a family member's medications to HealthVault from their pharmacy, run an Advanced Drug Safety survey of those medications and search for any symptoms they're having in PharmaSURVEYOR. Their safety survey will reveal which of their symptoms may actually be side effects, the medications that are more likely causing these and possible substitute drugs that can reduce their risk. The Advanced Drug Safety survey can be used in collaboration with their doctor to identify and diagnose those problems and get them resolved."

PharmaSURVEYOR is the only technology that goes beyond interaction checking to help reveal and reduce combined risks - the risks that add up across the drugs in a regimen even in the absence of chemical interactions. Combined risks were responsible for the death of Heath Ledger and other celebrities, whose drugs did not interact yet combined to lethal effect. While celebrity fatalities are highly visible, adverse effects and interactions are responsible for one in ten deaths in the U.S. - amounting to 4,000 fatalities every week - and have been estimated to cost the U.S. economy over $177 billion annually.

"Drug interaction checkers only flag interaction problems, not combined risks, and they don't help to resolve any problems; PharmaSURVEYOR does!" said Mr. Von Schweber. "PharmaSURVEYOR enables the HealthVault user to perform 'what-if' analyses, like using a spreadsheet, to simulate and evaluate the safety impact of changes to their drug regimen. There's nothing else like it."

About PharmaSURVEYOR

PharmaSURVEYOR, the most advanced drug safety utility, goes far beyond drug interaction checkers, is free to consumers at http://www.pharmasurveyor.com and is available as an online service for integration with healthcare websites, EMR, EHR, PHR and medical applications including Drug Utilization Review, Medication Therapy Management and Medication Reconciliation. For more information, contact Linda Von Schweber at linda@pharmasurveyor.com, (877) 797-8783 x102.

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE PharmaSURVEYOR
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. IMAGINE Software Unveils Advanced IMAGINEradiology(TM) Features
2. I-SPY trial offers key insights into locally advanced breast cancer
3. Vaccine shows therapeutic promise against advanced melanoma
4. Study shows drug combination improves outcome for advanced non-small cell lung cancer
5. Chemo Alone Is Best for Advanced Colon Cancer
6. 1 in 10 advanced colon cancer patients worry about prescription drug costs
7. One in ten advanced colon cancer patients worry about prescription drug costs
8. Advanced Life Sciences Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on Restanza(TM) (cethromycin)
9. More Living Longer With Advanced Colon Cancer
10. Advanced Technologies Pump Growth Into European Cardiac Rhythm Management Market, Affirms Frost & Sullivan
11. Advanced Prostate Cancer Deadlier in Younger Men
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the ... Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , “We ... new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, ... the latter, setting the bar too high can result in disappointment, perhaps even self-loathing. ... toward their goal. , Research from PsychTests.com reveals that behind the ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
Breaking Medicine Technology: